Critical Thinking about Serious Infections - Case-Based Reasoning to Optimize Patient Management: Module 3: Gram-negative Bacterial Infections

Thursday, March 1, 2018, 12:00 AM - Friday, February 28, 2020, 11:59 PM

AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

There are 3 modules for 1 CME/CE credit each. For each module, complete the pre-test, review the 4 cases, fill in the intra-activity questions, complete post-test and evaluation to receive credit. Passing grade is 70% and unlimited attempts. Patients who are immunocompromised or critically ill represent a particularly vulnerable population for infectious disease. One of the most common infections in immunosuppressed patients, including hematopoietic and solid organ transplant recipients, is cytomegalovirus (CMV). Infections caused by Gram-negative bacteria are also a significant concern in immunocompromised or critically ill patients. Management of both CMV and Gram-negative bacterial infections can be complicated by multi-drug resistance, which limits treatment options and negatively impacts outcomes. New options for preventing and managing these serious infections have recently been introduced, and other agents are in late stages of clinical development.

This activity has been designed to help clinicians analyze and apply best practices in managing serious infections in immunocompromised and critically ill patients. The program consists of 3 modules, each with 4 clinically-relevant cases involving serious infections that impact immunocompromised or critically ill patients, including CMV and multi-drug-resistant Gram-negative bacterial infections. This interactive online case-based format allows you to reflect on your own clinical decision making, and compare your decisions with those of an expert panel. Each module also provides the opportunity to review key risk factors for infections, issues that may impact therapeutic choices, and recently approved and investigational agents.

For Free Online Certified CME go to https://criticalthinkingcme.com/

1. List risk factors associated with cytomegalovirus (CMV) and multi-drug-resistant (MDR) gram-negative bacterial (GNB) infections in immunosuppressed or critically ill patients
2. Describe currently available and investigational therapeutic options for preventing and treating cytomegalovirus infections
3. Evaluate best practices and investigational options for the antibiotic treatment of MDR GNB infections in immunocompromised and critically ill patients.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Context Healthcare Group. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this Enduring Material Activity for a maximum of 3 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of South Carolina College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is accredited for 1.0 home study contact hours (0.1 CEUs)of application-based programming for pharmacists (ACPE 0062-9999-18-036-H01-P, 0062-9999-18-037-H01-P, 0062-9999-18-038-H01-P).

Credit Designation

To claim ACPE credit and have this credit submitted to the NABP CPE Monitor, the pharmacist-specific registration and evaluation must be completed per the instructions which will be provided at the completion of each home study. Release date: March 1, 2018. Expiration date February 28, 2019.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA, or FDA-approved agents that do not have an indication for the specific area being discussed. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s condition and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

No faculty are available for this activity at this time.

This activity is supported by an independent education grant from Merck & Co., Inc.